You are here

BeiGene

BeiGene expands pipeline and hops on board a quest to cure hep B, inking a $540M deal with a fellow upstart biotech

BeiGene expands pipeline and hops on board a quest to cure hep B, inking a $540M deal with a fellow upstart biotech

Endpoints

Assembly Biosciences

Flag link:

Chinese Biotech Beigene to Raise $2.1 Billion in Share Sale

Chinese Biotech Beigene to Raise $2.1 Billion in Share Sale

Bloomberg

Flag link:

Important catalysts approach for smaller biotechs

Important catalysts approach for smaller biotechs

EP Vantage

Turning Point Therapeutics

Intra-Cellular Therapies

clinical trials

Flag link:

BeiGene reports positive Phase III interim analysis for lung cancer drug

BeiGene reports positive Phase III interim analysis for lung cancer drug

MedCity News

clinical trials

non-squamous non-small cell lung cancer

Flag link:

BeiGene’s Tislelizumab Could Challenge Merck’s Keytruda in the Checkpoint Inhibitor Market

BeiGene’s Tislelizumab Could Challenge Merck’s Keytruda in the Checkpoint Inhibitor Market

BioSpace

non-small cell lung cancer

Flag link:

Amgen wades deeper into Asia with full control of an Astellas Japanese JV

Amgen wades deeper into Asia with full control of an Astellas Japanese JV

Fierce Pharma

Flag link:

BeiGene lung cancer treatment meets main goal in late-stage study

BeiGene lung cancer treatment meets main goal in late-stage study

Reuters

clinical trials

Flag link:

Amgen to Sell Cancer Drugs in China Thanks to $2.7B Deal with BeiGene

Amgen to Sell Cancer Drugs in China Thanks to $2.7B Deal with BeiGene

Xtalks

Flag link:

Boehringer cleared to manufacture BeiGene’s cancer drug for Chinese market

Boehringer cleared to manufacture BeiGene’s cancer drug for Chinese market

Pharmaforum

Boehringer Ingelheim

drug manufacturing

Flag link:

3 Blockbuster Cancer Drug Launches to Watch in 2020

3 Blockbuster Cancer Drug Launches to Watch in 2020

Motley Fool

Seattle Genetics

Flag link:

Corporate and regulatory developments over the Christmas period

Corporate and regulatory developments over the Christmas period

EP Vantage

Ono Pharmaceutical

Xyphos Biosciences

Flag link:

5 New Drug Approvals the FDA Gave Top Priority

5 New Drug Approvals the FDA Gave Top Priority

Motley Fool

Global Blood Therapeutics

Vertex Pharmaceuticals

Flag link:

FDA Approves 5 New Costly Drugs Well Ahead of PDUFA Dates

FDA Approves 5 New Costly Drugs Well Ahead of PDUFA Dates

RAPS.org

Vertex Pharmaceuticals

Global Blood Therapeutics

Flag link:

China's BeiGene gets FDA approval for drug to treat rare form of lymphoma

China's BeiGene gets FDA approval for drug to treat rare form of lymphoma

Yahoo/Reuters

mantle cell lymphoma

Flag link:

Ahead of FDA decision on BTK drug, Amgen-partnered BeiGene scores China OK for PD-1

Ahead of FDA decision on BTK drug, Amgen-partnered BeiGene scores China OK for PD-1

Endpoints

Flag link:

Amgen pays $2.7bn to harness BeiGene’s China marketing muscle

Amgen pays $2.7bn to harness BeiGene’s China marketing muscle

Pharmaforum

Flag link:

BeiGene's first U.S. NDA tests global development strategy

BeiGene's first U.S. NDA tests global development strategy

BioCentury

drug development

Flag link:

The 2 Biggest Casualties From the Celgene-Bristol-Myers Merger (So Far)

The 2 Biggest Casualties From the Celgene-Bristol-Myers Merger (So Far)

Yahoo/Motley Fool

Bristol-Myers Squibb

Flag link:

As Bristol-Myers/Celgene tie up loose ends, BeiGene pockets $150M from PD-1 breakup

As Bristol-Myers/Celgene tie up loose ends, BeiGene pockets $150M from PD-1 breakup

Endpoints

Bristol-Myers Squibb

Flag link:

The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs

The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs

Yahoo/Benzinga

Akero Therapeutics

Dermavant Sciences

Prevail Therapeutics

Stoke Therapeutics

Flag link:

Pages